Our corporate headquarters are in Los Angeles, California.
Immix Biopharma is incorporated under the laws of the State of Delaware.
Our fiscal year is January 1st to December 31st.
We have been approved to list our shares of common stock on The Nasdaq Capital Market under the symbol “IMMX” upon our satisfaction of Nasdaq’s initial listing criteria, including the completion of initial public offering.
Immix Biopharma has not historically paid any dividends and does not expect to pay dividends in the foreseeable future.
Immix Biopharma’s transfer agent is Philadelphia Stock Transfer.
You may contact PST at: Philadelphia Stock Transfer, Inc. 2320 Haverford Road, Suite 230, Ardmore, PA 19003 (484) 416-3124
KMJ Corbin & Company
Sheppard, Mullin, Richter & Hampton LLP
Additional information about Immix Biopharma can be found on our website and in our public filings with the United States Securities & Exchange Commission.
Our latest corporate news releases and financial reports can be found on the Investors page of our website.
These documents can be found on the SEC’s EDGAR system at www.sec.gov or on the Investors page of our website.
Information concerning our Executive Management team and Board of Directors can be found on our website.
You can contact us by using the Contact Us page on our website.